Status:

RECRUITING

tACS to Enhance Language Abilities

Lead Sponsor:

University of Pennsylvania

Conditions:

Stroke

Aphasia, Acquired

Eligibility:

All Genders

18-85 years

Phase:

NA

Brief Summary

The goal of this study is to see if transcranial alternating current stimulation (tACS) can be used to enhance language abilities in people with post-stroke aphasia. Participants will receive real and...

Detailed Description

This research will investigate whether transcranial alternating current stimulation (tACS), a form of noninvasive brain stimulation, can be used to enhance language abilities in people with aphasia (P...

Eligibility Criteria

Inclusion

  • Inclusion Criteria for Persons with Aphasia:
  • Presence of aphasia
  • Suffered a single, left hemisphere stroke
  • Stroke ≥6 months old (chronic) at the time of enrollment
  • Inclusion Criteria for Healthy Controls:
  • Right-handedness
  • Must be able to understand the nature of the study, and give informed consent
  • Exclusion criteria for Persons with Aphasia:
  • Inability to understand the nature of the study
  • Marked naming impairment
  • Impaired non-verbal, conceptual processing
  • History of significant medical or neurological disorder (other than stroke)
  • History of significant or poorly controlled psychiatric disorders
  • Current abuse of alcohol or drugs, prescription or otherwise
  • Nursing a child, pregnancy, or intent to become pregnant during the study
  • Clinically significant hearing loss
  • Contraindications to tACS
  • Contraindications to MRI
  • Exclusion Criteria for Healthy Controls
  • Diagnosis of a neurodegenerative disease or clinically significant cognitive complaint
  • Any unrelated neurologic or physical condition that impairs communication ability
  • History of unrelated neurological conditions including but not limited to traumatic brain injury, stroke, or small vessel disease that has resulted in a neurologic deficit
  • Any additional neurological condition that would likely reduce the safety of study participation, including central nervous system (CNS) vasculitis, intracranial tumor, intracranial aneurysm, multiple sclerosis or arteriovenous malformations
  • A medically unstable cardiopulmonary or metabolic disorder
  • Terminal illness associated with survival \<12 months
  • Major active psychiatric illness that may interfere with required study procedures or treatments as determined by the enrolling physician
  • Current abuse of alcohol or drugs, prescription or otherwise
  • Contraindications to tACS
  • Contraindications to MRI

Exclusion

    Key Trial Info

    Start Date :

    July 12 2024

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    August 31 2028

    Estimated Enrollment :

    120 Patients enrolled

    Trial Details

    Trial ID

    NCT06092814

    Start Date

    July 12 2024

    End Date

    August 31 2028

    Last Update

    August 8 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University of Pennsylvania

    Philadelphia, Pennsylvania, United States, 19104